| Members |
targetComponentId |
| Androblastoma, no International Classification of Diseases for Oncology subtype |
Androblastoma of uncertain behavior (morphologic abnormality) |
| Androstanedione |
Androstenedione |
| Androstenolone |
Dehydroepiandrosterone |
| anémie causée par une substance |
Anemia |
| Anemia due to chemical agent |
Anemia |
| Anemia of chronic disorder, NOS |
Anemia |
| Anemia unspecified |
Anemia |
| Anesthetic gas |
Gaseous dose form |
| Angina decubitus NOS |
Angina decubitus |
| Angina self management plan |
Angina self management plan |
| Angioblastic meningioma |
Hemangioblastic meningioma |
| Angiocentric T-cell lymphoma |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma |
Natural killer-/T-cell lymphoma, nasal and nasal-type (morphologic abnormality) |
| Angioendotheliomatosis |
Intravascular large B-cell lymphoma (disorder) |
| Angioendotheliomatosis |
Intravascular large B-cell lymphoma (disorder) |
| Angiofibroma, no International Classification of Diseases for Oncology subtype |
Angiofibroma (morphologic abnormality) |
| Angioimmunoblastic lymphadenopathy with dysproteinemia |
Angioimmunoblastic T-cell lymphoma (disorder) |
| Angioplasty - action |
Dilation - action |
| Angiotensin-converting-enzyme inhibitor allergy |
Non-allergic hypersensitivity to angiotensin-converting enzyme inhibitor |
| Angle-closure glaucoma - borderline |
Angle closure glaucoma suspect (disorder) |
| Anhydrohydroxy progesterone preparation |
Product containing ethisterone (medicinal product) |
| Anidulafungin 100mg powder for injection solution vial |
Product containing only anidulafungin (medicinal product) |
| Animal ear washing |
Irrigation of ear |
| Anion |
Electrolyte anion (substance) |
| Anisocytosis of red cells (morphologic abnormality) |
Anisocytosis, red cells (finding) |
| Ankle brachial pressure index management plan |
Ankle brachial pressure index management plan (record artifact) |
| Ankle somatic dysfunction |
Somatic dysfunction of ankle region (finding) |
| Ankylosing vertebral hyperostosis |
Disseminated idiopathic skeletal hyperostosis |
| Annual |
Annual |
| Annuloplasty - action |
Reconstruction - action |
| anomalous sentence repetition test - Weeks |
Anomalous sentences repetition test |
| Anosmic aphasia |
Anomic aphasia |
| Anser caerulescens |
Chen caerulescens (organism) |
| Anser caerulescens caerulescens |
Chen caerulescens caerulescens (organism) |
| Antabuse overdose |
Disulfiram overdose (disorder) |
| Antabuse poisoning |
Disulfiram poisoning (disorder) |
| Antazoline sulfate+xylometazoline hydrochloride |
Product containing antazoline and xylometazoline (medicinal product) |
| Antecubital arm fasciocutaneous flap |
Fasciocutaneous flap |
| Antecubital arm flap |
Flap (substance) |
| Antenatal Anti-D prophylaxis refused |
Administration of human anti-D immunoglobulin declined |
| Antenatal blood group screening NOS |
Antenatal blood group screening status |
| Antenatal blood group screening NOS |
Antenatal blood group screening status |
| Antenatal care: recurrent aborter |
Recurrent miscarriage |
| Antenatal chorionic villus sampling refused |
Sampling of chorionic villus declined |
| Antenatal hepatitis B blood screening test refused |
Antenatal screening for viral hepatitis type B declined |
| Antenatal human immunodeficiency virus blood screening test refused |
Antenatal screening for human immunodeficiency virus declined (situation) |
| Antenatal scan unable to confirm pregnancy |
Antenatal scan unable to confirm pregnancy (finding) |
| Antenatal thalassemia blood screening test refused |
Antenatal thalassemia screening declined (situation) |
| Antenatal ultrasound confirms ectopic pregnancy |
Antenatal ultrasound confirms ectopic pregnancy (finding) |
| Antenatal ultrasound confirms intrauterine pregnancy |
Antenatal ultrasound confirms intrauterine pregnancy (finding) |
| Antepartum haemorrhage NOS |
Antepartum hemorrhage |
| Antepartum haemorrhage NOS |
Antepartum hemorrhage |
| Antepartum hemorrhage NOS |
Antepartum hemorrhage |
| Antepartum hemorrhage due to disseminated intravascular coagulation |
Antepartum hemorrhage with disseminated intravascular coagulation (disorder) |
| Anterior cervical cord injury, without bony injury, C1-4 |
Anterior cervical spinal cord injury at C1-C4 level without spinal bone injury |
| Anterior cervical cord injury, without bony injury, C5-7 |
Anterior cervical spinal cord injury, without spinal bone injury, C5-7 (disorder) |
| Anterior cervical flap |
Flap (substance) |
| Anterior chest flap |
Flap (substance) |
| Anterior thigh flap |
Flap (substance) |
| Anterior tibial fasciocutaneous flap |
Anterior tibial artery fasciocutaneous flap (substance) |
| Anterior tibial flap |
Anterior tibial artery flap (substance) |
| Antheor temporary caval filter |
Temporary vena cava filter |
| Anthralin 0.2% cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.2% cutaneous cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.4% cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthralin 0.4% cutaneous cream |
Product containing only dithranol in cutaneous dose form (medicinal product form) |
| Anthraquinone dye |
Anthraquinone |
| anti-D (Rh) immunoglobulin 1250iu/mL injection solution 1mL prefilled syringe |
Human anti-D immunoglobulin 1250 unit/mL solution for injection |
| Anti-D (Rh) immunoglobulin adverse reaction |
Human anti-D immunoglobulin adverse reaction (disorder) |
| Anti-D globulin NOS |
Administration of human anti-D immunoglobulin (procedure) |
| Anti-D globulin NOS |
Administration of human anti-D immunoglobulin (procedure) |
| immunoglobulines anti-D administrées |
Human anti-D immunoglobulin administered (situation) |
| Anti-D globulin given |
Human anti-D immunoglobulin administered (situation) |
| immunoglobuline anti-D requise |
Administration of human anti-D immunoglobulin needed (situation) |
| Anti-D globulin needed |
Administration of human anti-D immunoglobulin needed (situation) |
| Anti-D-Immunglobulin verabreicht |
Human anti-D immunoglobulin administered (situation) |
| Anti-D immunoglobulin given |
Human anti-D immunoglobulin administered (situation) |
| Anti-endomysium antibody |
Endomysial antibody |
| Anti-gliadin antibody |
Gliadin antibody |
| agent antigoutteux |
Uricosuric agent |
| Antianaemic agent |
Medicinal product acting as antianemic agent (product) |
| Antibiotic |
Medicinal product acting as antibacterial agent (product) |
| Antibiotic antifungal allergy |
Allergy to drug |
| Antibiotic antituberculosis agent |
Antituberculosis agent |
| Antibiotic antituberculosis drug adverse reaction |
Antituberculous drug adverse reaction |
| Antibiotic antituberculosis drug allergy |
Allergy to drug |
| Antibody by type |
Antibody |
| Antibody-mediated cytolysis |
Immune hypersensitivity disorder by mechanism (disorder) |
| Anticardiolipin antibody |
Cardiolipin antibody |
| Anticoagulant therapy |
Administration of anticoagulant |
| Antidiabetic agent preparation |
Medicinal product acting as antidiabetic agent (product) |
| Antiepileptics |
Medicinal product acting as anticonvulsant agent (product) |
| Antifreeze |
Automotive antifreeze (substance) |
| Antigen to antibody in Kell blood group system |
Antibody to antigen in Kell blood group system (substance) |
| Antigout therapeutic role |
Uricosuric therapeutic role |
| Antihemophilic factor agent 1000 iu powder for conventional release solution for injection vial |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1000 iu powder for injection solution 5mL vial + diluent |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1500 iu powder for conventional release solution for injection vial |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 1500 iu powder for injection solution 5mL vial + diluent |
Antihemophilic factor agent only product |
| Antihemophilic factor agent 500 iu powder for conventional release solution for injection vial |
Antihemophilic factor agent only product |
FHIR